BridgeBio Pharma, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 74.95 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 14.65B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Details
| Name | BridgeBio Pharma, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 1003 |
| Founded | 2015 |
| Ipo Date | 2019-06-27 |
| Ceo | Neil Kumar |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 17.00 |
| Isin | US10806X1028 |
| Cusip | 10806X102 |
| Cik | 1743881 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Eric Michael David J.D., M.D., Ph.D. | Chief Executive Officer of Gene Therapy |
| Dr. Neil Kumar Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Dr. Thomas Trimarchi Ph.D. | Chief Financial Officer and President |
| Dr. Charles J. Homcy M.D. | Co-Founder, Chairman of Pharmaceuticals and Lead Director |
| Dr. Frank P. McCormick Ph.D. | Co-Founder, Chairman of Oncology and Director |
| Maricel M. Apuli | Chief Accounting Officer |
| Dr. Uma Sinha Ph.D. | Chief Scientific Officer |
| Dr. Richard H. Scheller Ph.D. | Chairman of Research and Development |
| Eli M. Wallace Ph.D. | Chief Scientific Officer of Oncology |
| Matthew Outten CPC, MBA | Chief Commercial Officer |
Contact
| Address | 3160 Porter Drive, Suite 250, Palo Alto, California 94304, United States |
| Phone | 650 391 9740 |
| Website | https://bridgebio.com |